BioSante Turns to Nonprofit for Melanoma Vaccine Development
By Catherine Shaffer
Friday, July 22, 2011
As a way of getting clinical trials "under way and successfully concluded," BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., has licensed its melanoma vaccine to the John P. Hussman Foundation for $100,000 up front, with up to $39 million in milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.